Multisystem derangements in frailty and sarcopenia: a source for biomarker discovery.
Journal
Current opinion in clinical nutrition and metabolic care
ISSN: 1473-6519
Titre abrégé: Curr Opin Clin Nutr Metab Care
Pays: England
ID NLM: 9804399
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
pubmed:
4
3
2022
medline:
30
6
2022
entrez:
3
3
2022
Statut:
ppublish
Résumé
Multisystem derangements, encompassing metabolic, musculoskeletal and stress-response systems, occur during aging and are associated with the development of physical frailty and sarcopenia. These modular changes are relevant sources for the identification of biomarkers for the two conditions. Here, we provide an up-to-date overview on existing biomarkers of physical frailty and sarcopenia and discuss emerging approaches for biomarker discovery. Inflammatory, metabolic and hematologic markers are shared between physical frailty and sarcopenia. Gut microbial derivatives and damage-associated molecular patterns transferred via extracellular vesicles have been indicated as possible gut-muscle axis regulators and candidate markers of physical frailty and sarcopenia. Mediators of metabolic, musculoskeletal and stress-response system dysregulation are shared by physical frailty and sarcopenia and indicate the existence of common pathophysiological pathways. Multiplatform biomarker analyses have been proposed as an innovating approach for tracking the multifaceted and dynamic nature of physical frailty and sarcopenia. Upon validation, the identified biomarkers may support diagnostic makeup and tracking of the two conditions in both research and clinical settings.
Identifiants
pubmed: 35238804
doi: 10.1097/MCO.0000000000000828
pii: 00075197-202205000-00008
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-177Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Fried LP, Cohen AA, Xue Q-L, et al. The physical frailty syndrome as a transition from homeostatic symphony to cacophony. Nat Aging 2021; 1:36–46.
Oviedo-Briones M, Laso AR, Carnicero JA, et al. A comparison of frailty assessment instruments in different clinical and social care settings: the Frailtools Project. J Am Med Dir Assoc 2021; 22:607.e7–607.e12.
Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol Ser A Biol Sci Med Sci 2001; 56:M146–M157.
Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005; 173:489–495.
Coelho-Junior HJ, Calvani R, Picca A, et al. Protein-related dietary parameters and frailty status in older community-dwellers across different frailty instruments. Nutrients 2020; 12:508.
Hoogendijk EO, Afilalo J, Ensrud KE, et al. Frailty: implications for clinical practice and public health. Lancet 2019; 394:1365–1375.
Faller JW, Pereira DDN, de Souza S, et al. Instruments for the detection of frailty syndrome in older adults: a systematic review. PLoS One 2019; 14:e0216166.
Landi F, Calvani R, Cesari M, et al. Sarcopenia: an oon current definitions, diagnosis and treatment. Curr Protein Pept Sci 2018; 19:633–638.
Guerville F, De Souto Barreto P, Ader I, et al. Revisiting the hallmarks of aging to identify markers of biological age. J Prev Alzheimers Dis 2020; 7:56–64.
Rodriguez-Manas L, Araujo de Carvalho I, Bhasin S, et al. ICFSR task force perspective on biomarkers for sarcopenia and frailty. J Frailty Aging 2020; 9:4–8.
Gomez-Cabrero D, Walter S, Abugessaisa I, et al. A robust machine learning framework to identify signatures for frailty: a nested case-control study in four aging European cohorts. GeroScience 2021; 43:1317–1329.
Picca A, Calvani R, Cesari M, et al. Biomarkers of physical frailty and sarcopenia: coming up to the place? Int J Mol Sci 2020; 21:5635.
Marzetti E, Guerra F, Calvani R, et al. Circulating mitochondrial-derived vesicles, inflammatory biomarkers and amino acids in older adults with physical frailty and sarcopenia: a preliminary BIOSPHERE Multi-Marker Study using sequential and orthogonalized covariance selection - linear discriminant Analysis. Front Cell Dev Biol 2020; 8:564417.
Varadhan R, Russ DW, Gabr RE, et al. Relationship of physical frailty to phosphocreatine recovery in muscle after mild exercise stress in the oldest-old women. J Frailty Aging 2019; 8:162–168.
Lewsey SC, Weiss K, Schar M, et al. Exercise intolerance and rapid skeletal muscle energetic decline in human age-associated frailty. JCI Insight 2020; 5:e141246.
Le NP, Varadhan R, Fried LP, Cappola AR. Cortisol and dehydroepiandros-terone response to adrenocorticotropic hormone and frailty in older women. J Gerontol A Biol Sci Med Sci 2021; 76:901–905.
Ghachem A, Fried LP, Legault V, et al. Evidence from two cohorts for the frailty syndrome as an emergent state of parallel dysregulation in multiple physiological systems. Biogerontology 2021; 22:63–79.
Bellavance MA, Rivest S. The HPA - immune axis and the immunomodulatory actions of glucocorticoids in the brain. Front Immunol 2014; 5:136.
El Assar M, Angulo J, Rodríguez-Mañas L. Frailty as a phenotypic manifestation of underlying oxidative stress. Free Radic Biol Med 2020; 149:72–77.
Straub RH. Interaction of the endocrine system with inflammation: a function of energy and volume regulation. Arthritis Res Ther 2014; 16:203.
Calvani R, Picca A, Marini F, et al. Identification of biomarkers for physical frailty and sarcopenia through a new multimarker approach: results from the BIOSPHERE study. GeroScience 2020; 43:727–740.
Picca A, Coelho-Junior HJ, Calvani R, et al. Biomarkers shared by frailty and sarcopenia in older adults: a systematic reviewand meta-analysis. Ageing Res Rev 2022; 73:101530.
Steinmeyer Z, Delpierre C, Soriano G, et al. Hemoglobin concentration; a pathway to frailty. BMC Geriatr 2020; 20:202.
Tseng SH, Lee WJ, Peng LN, et al. Associations between hemoglobin levels and sarcopenia and its components: results from the I-Lan longitudinal study. Exp Gerontol 2021; 150:111379.
El Assar M, Angulo J, Carnicero J, et al. Association between telomere length, frailty and death in older adults. GeroScience 2021; 43:1015–1027.
Rodríguez-Manas L, Angulo J, Carnicero J, et al. Dual effects of insulin resistance on mortality and function in nondiabetic older adults: findings from the Toledo Study of Healthy Aging. GeroScience 2021; doi:10.1007/s11357-021-00384-394. [Online ahead of print].
doi: 10.1007/s11357-021-00384-394.
Picca A, Calvani R, Sirago G, et al. Molecular routes to sarcopenia and biomarker development: per aspera ad astra. Curr Opin Pharmacol 2021; 57:140–147.
Marzetti E, Picca A, Marini F, et al. Inflammatory signatures in older persons with physical frailty and sarcopenia: the frailty ‘cytokinome’ at its core. Exp Gerontol 2019; 122:129–138.
Picca A, Coelho-Junior HJ, Cesari M, et al. The metabolomics side of frailty: toward personalized medicine for the aged. Exp Gerontol 2019; 126:110692.
Seeman TE, McEwen BS, Rowe JW, Singer BH. Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. Proc Natl Acad Sci USA 2001; 98:4770–4775.
Howlett SE, Rockwood MRH, Mitnitski A, Rockwood K. Standard laboratory tests to identify older adults at increased risk of death. BMC Med 2014; 12:171.
Muscedere J, Kim PM, Afílalo J, et al. Proceedings of the Canadian Frailty Network Workshop: identifying biomarkers of frailty to support frailty risk assessment, diagnosis and prognosis. Toronto, January 15, 2018. J Frailty Aging 2019; 8:106–116.
Calvani R, Picca A, Marini F, et al. The ‘BlOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons’ (BIOSPHERE) study: rationale, design and methods. Eur J Intern Med 2018; 56:19–25.
Van Pelt DW, Vechetti IJ, Lawrence MM, et al. Serum extracellular vesicle miR-203a-3p content is associated with skeletal muscle mass and protein turnover during disuse atrophy and regrowth. Am J Physiol Cell Physiol 2020; 319:C419–C431.
Justice JN, Ferrucci L, Newman AB, et al. A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. GeroScience 2018; 40:419–436.